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ABSTRACT
Cognitive functions can be assessed and followed up over a period of time with cognitive evoked poten-
tials (CEP) P300� In this context, brainstem auditory evoked potentials (BAEP) are most commonly used, 
but visual evoked potentials (VEP) are utilized as well� The research in this area has demonstrated that 
these techniques could be used as a supplemental method in diagnostics of numerous diseases such 
as Alzheimer’s disease, mild cognitive impairment, vascular dementia, epilepsy, craniocerebral trauma, 
Parkinson’s disease, multiple sclerosis, and other degenerative diseases� In addition, P300 can also be 
used as an auxiliary method in the diagnostics of mental disorders conditions such as schizophrenia, 
panic disorders, narcotic drug addiction, nicotinism, alcoholism, etc� The method assists in monitoring the 
course of diseases leading to encephalopathy, such as liver and kidney damage and grave anaemia� The 
advantages of P300 testing are easy application, non-invasiveness, and an unlimited number of potential 
applications� Moreover, the results obtained with this method are measurable and can be compared�
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INTRODUCTION
Neuropsychological tests are applied in assessing 
cognitive, cortical functions in patients with neuro-
logical and mental diseases, brain trauma, and dam-
age resulting from other diseases (1-3). Event-related 
potential (ERP) is a non-invasive electrophysio-
logical method. It can be used to assess different 
aspects of human cognitive information processing. 
ERP components such as auditory evoked P300, 
associated with cognitive processes (i.e.,  attention 
and orientation), show low amplitude and long 
latency in acute and chronic diseases (4-6). P300 
testing is an unbiased and non-invasive method, 
standardized for assessing cognitive processes (7-10). 
We have reviewed the existing literature in this field 
to better understand the role of P300 testing in 
diagnostics of different diseases.
Review of literature
We performed a systematic literature search and 
review of publications identified in the MEDLINE 
database (searched through September 2009). The 
search term was “P300, cognitive”, and the search 
was limited to clinical trials and articles in English. 
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The search was extended by the review of bibliog-
raphies from pertinent original reports and review 
articles. The research included 1212 references on 
P300.
P300 testing has been demonstrated to be a method 
of choice in differential diagnostic assessment of 
neurological and psychiatric diseases (Table  1). 
Clinical research showed significant changes in 
P300 parameters, such as lowered amplitude 
and extended latency, in patients with dementia, 
Alzheimer’s disease, and mild cognitive impairment 
[MCI] (11-19). A smaller number of studies indi-
cated changes in P300 in patients with epilepsy, 
and in those taking antiepileptic drugs (10,20). 
A  few studies indicated specific changes in ampli-
tude and latency of P300 in clinically isolated syn-
drome and multiple sclerosis, as well as effects of 
interferon beta-1b to cognitive functions, even the 
P300 characteristics (21-23). Some studies indi-
cated changes in P300 characteristics in patients 
with Parkinson’s disease (the changes correlated with 
the degree of the disease determined according to 
the Hoehn and Yahr scale), growth hormone defi-
ciency, Huntington’s disease, Tourette syndrome, 
and narcolepsy (2,9,24-27). Changes of P300 char-
acteristics, lowered amplitude, and extended latency 
have also been noticed in schizophrenia (28-36), 
post-traumatic stress disorder (36,37,40), endog-
enous psychoses (38-41), panic disorder (42-45), 
and depressive patients (46,47). Additionally, a 
few papers described changes of P300 in impulsive 
aggressive criminals and obsessive-compulsive disor-
der (48,49).
Cognitive damage often results from craniocere-
bral trauma. The damage and gravity dysfunction 
are assessed by neuropsychological and neuro-
physiological analysis, where cognitive evoked 
potentials (CEP) P300 is among the preferred 
methods (50-53).
Some studies reported changes in P300 amplitude 
and latency in cases of chronic consumption of nic-
otine, alcohol, as well as cannabis, opioids, cocaine, 
and ecstasy (Table 2) (8,54-60).
Isolated research has been performed on CEP P300 
in patients with epilepsy taking different antiepi-
leptic drugs, such as: topiramate, valproate, and 
lamotrigine (61-63). These studies were based on 
measuring and comparing CEP P300 parameters 
while the patients were taking the drugs.
Cognitive damage in some systemic diseases can be 
assessed with CEP P300 (64-78). Improvements in 
TABLE 1.	Neurological	and	psychiatric	diseases	with	confirmed	changes	of	P300	wave	parameters
Disease Studies
Dementia
Alzheimer’s	disease
Mild	cognitive	impairment
Epilepsy
Clinically	isolated	syndrome
Multiple	sclerosis
Parkinson’s	disease
Growth	hormone	deficiency
Huntington’s	disease
Narcolepsy
Tourette	syndrome
Schizophrenia
Endogenous	psychoses
Post-traumatic	stress	disorder
Panic	disorder
Depression
Impulsive	aggressive	behavior
Obsessive-compulsive	disorder	
Uemura	et	al.	(11),	Egerházi	et	al.	(17),	Egerházi	et	al.	(18)
Bennys	et	al.	(12),	Juckel	et	al.	(14),	Yener	et	al.	(15),	van	Deursen	et	al.	(16),	Egerházi	
et	al.	(17),	Egerházi	et	al.	(18)
Bennys	et	al.	(12),	Golob	et	al.	(13),	van	Deursen	et	al.	(16),	Egerházi	et	al.	(17),	Egerházi	
et	al.	(18),	Pappaliagkas	et	al.	(19)
Zgorzalewicz	(10),	Ozmenek	et	al.	(20)
Kocer	et	al.	(21)
Magnié	et	al.	(22),	Flechter	et	al.	(23)
Hayashi	et	al.	(24)
Tanriverdi	et	al.	(25),	Braverman	et	al.	(26)
Beste	et	al.	(9)
Saletu	et	al.	(2)
Thibault	et	al.	(27)
Ford	et	al.	(28),	van	der	Stelt	and	Belger	(29),	Takahashi	et	al.	(30),	Zhang	et	al.	(31),	Higuchi	
et	al.	(32),	Wood	et	al.	(33),	Ozgürdal	et	al.	(1),	Sumiyoshi	et	al.	(34),	Turetsky	et	al.	(35),	Galletly	
et	al.	(36),	Veltmeyer	et	al.	(37)
Lebedeva	et	al.	(38),	Lebedeva	et	al.	(39),	Bramon	et	al.	(40)
Veltmeyer	et	al.	(37),	Shucard	et	al.	(41)
Tuter	(42),	Gordeev	(43),	Gordeev	(44),	Gordeev	(45)
Coullaut-Valera	García	et	al.	(46),	Zhang	et	al.	(47)
Zukov	et	al.	(48)
Gohle	et	al.	(49)
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the treatment and recovery can be followed in the 
same way. So far, changes in P300 characteristics, 
amplitude, and latency have been monitored in the 
following systemic diseases: anaemia, hepatic insuf-
ficiency, diabetes mellitus type 1, hypothyroidism, 
chronic obstructive pulmonary disease (COPD), 
organophosphorus insecticide poisoning, and 
HIV-1 neurologically asymptomatic seropositive 
individuals (Table 3).
DISCUSSION
Cognitive abilities include a number of qualitative 
characteristics that can be assessed with different neu-
ropsychological tests. Recently, neurophysiological 
tests with CEP P300 are gaining attention (79-81). 
During the testing procedure, both auditory and 
visual stimuli are used. These are referred to as brain-
stem auditory evoked potentials (BAEP) and visual 
evoked potentials (VEP), and BAEP are used more 
frequently. In addition, comparative analysis of neu-
ropsychological and neurophysiological P300 tests 
showed a statistically significant correlation, with 
high specificity and sensitivity (79-83). Changes 
of CEP P300 are characterized by extended latency 
and low wave amplitude. Numerous studies showed 
alterations of CEP P300 in neurological and psychi-
atric diseases, as well as consequences of traumatic 
damages of the brain, that is, craniocerebral injuries 
(11-53). Different substances that cause addiction, 
from alcohol and nicotine to various opiates, lead 
to changes in cognitive functions, including changes 
in P300 parameters, due to brain damage (54-60). 
Moreover, with P300 testing, damage of cognitive 
functions resulting from taking different medi-
cines, especially antiepileptic drugs, can also be 
monitored (61-63). Additionally, P300 character-
istics help diagnosing cognitive damage resulting 
from systemic diseases, such as anaemia, uremia 
(renal insufficiency), hepatic encephalopathy, sys-
temic lupus erythematosus, diabetes mellitus, hypo-
thyreosis, as well as COPD (64-76). Moreover, 
cognitive function damage in patients with HIV-1 
neurologically asymptomatic seropositive can be 
assessed with P300 testing (78). Finally, changes of 
P300 parameters are observed in organophosphorus 
insecticide poisoning (77).
CEP P300 tests are easy to apply, can be repeated 
often, there are no unwanted side effects or radia-
tion, and the application is very simple. Also, the 
test is unbiased and a tested individual cannot influ-
ence the results. The test results (wave amplitude and 
latency) are expressed numerically. Therefore, the 
results can be easily compared at various stages of a 
disease, and the brain damage as well as the healing 
process can be monitored. All the mentioned above 
indicate that CEP P300 is a method of choice in 
differential diagnostics of cognitive functions. This 
is a preferred supplemental method in diagnostics of 
cognitive damage in clinical practice.
CONCLUSION
CEP P300 testing is a simple, quantitative, diagnos-
tic method used in diagnosing cognitive damage in 
TABLE 2.	 Substances	 that	 cause	 addiction	 and	 results	 in	
altered	P300
Addictive	substances Studies
Nicotine
Alcohol
Cannabis
Opioid
Cocaine
Ecstasy
Müller	et	al.	(8),	Guney	et	al.	(54)
Naziel	et	al.	(55),	Maurage	et	al.	(56)
Roser	et	al.	(57)
Singh	et	al.	(58)
Gooding	et	al.	(59)
de	Sola	et	al.	(60)
TABLE 3.	Systemic	diseases	that	cause	damage	to	cognitive	functions	measurable	with	P300
Disease Studies
Anaemia
Hepatic	encephalopathy
Neuropsychiatric	systemic	lupus	erythematosus
Uremia
Diabetes	mellitus	type	1
Hypothyroidism
Chronic	obstructive	pulmonary	disease
Organophosphorus	insecticide	poisoning
HIV-1	seropositive	subjects
Otero	et	al.	(64),	Khedr	et	al.	(65),	Kececi	et	al.	(66)
Reeves	et	al.	(67),	Teodoro	et	al.	(68),	Guerit	et	al.	(69)
Mostafa	et	al.	(70),	Buca	et	al.	(71)
Madan	et	al.	(72)
Cooray	et	al.	(73)
Nazliel	et	al.	(74),	Anjana	et	al.	(75)
Kirkil	et	al.	(76)
Dassanayake	et	al.	(77)
Amador	Romero	et	al.	(78)
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clinical practice. The main advantage of this method 
compared to other diagnostic methods is the ability 
to compare the measurement results easily and to 
monitor the progress of disease.
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